Medicare AdvantageCoverageMedium impact
MA08.151e, Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
Independence Blue Cross·Neurology, Geriatrics, Internal Medicine·Medical Policy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
Policy MA08.151e establishes coverage and medical necessity criteria for monoclonal antibodies directed against amyloid for Alzheimer's disease treatment. This recent policy (effective 01/01/2026) includes updates to coverage positions, reimbursement guidelines, medical coding requirements, and general clinical guidelines for this drug class.
Action Required
By 12/20/2025: Billing and clinical teams must obtain and review the complete MA08.151e policy text to identify specific HCPCS codes for amyloid-directed monoclonal antibodies (likely J-codes for biologics) and any associated CPT codes for administration or monitoring. Update billing system coverage rules, prior authorization protocols, and medical necessity templates accordingly. Providers must document medical necessity per policy criteria for all related claims. Clinical staff should review eligibility requirements and coding guidelines. Without proper implementation, claims for these therapies will be denied. Obtain policy details from the source URL provided and distribute to all relevant staff members.